Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous anti-GPC3-CAR T lymphocytes Ori-C101

A preparation of autologous T lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) specific for glypican-3 (GPC3) and a signal activation domain element, Ori, with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-GPC3-CAR T lymphocytes Ori-C101 specifically target and bind to GPC3-expressing tumor cells, resulting in tumor cell lysis. GPC3, a heparan sulfate proteoglycan (HSPG) and a member of the glypican family, is overexpressed on certain tumor cell types while minimally expressed on normal, healthy cells. GPC3 plays an important role in cellular proliferation and differentiation. Ori is able to enhance the expansion of memory T cells, abrogate the immunosuppressive tumor microenvironment (TME), and may enhance the anti-tumor activity and durability of CAR T cells Ori-C101.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:autologous anti-GPC3 CAR T cells Ori-C101
autologous GPC3-directed CAR T cells Ori-C101
CAR T cells Ori-C101
Code name:Ori C101
Ori-C101
OriC101
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search